<DOC>
	<DOCNO>NCT02736344</DOCNO>
	<brief_summary>The BioNIR Ridaforolimus Eluting Coronary Stent System single use device/drug combination product comprising : - Stent - mount Cobalt Chromium ( CoCr ) alloy base stent - Delivery System - Rapid Exchange ( RX ) Coronary System - Polymer matrix coat - Poly n-butyl methacrylate ( PBMA ) polymer coating ( CarboSil® ) - Ridaforolimus drug - Chemical Abstracts Service ( CAS ) Registry Number : 572924-54-0 The product indicate improve coronary luminal diameter patient symptomatic heart disease due lesion vessel reference diameter 2.5mm 4.25mm , include complex lesion .</brief_summary>
	<brief_title>BIONICS - Pharmacokinetics ( PK ) Trial</brief_title>
	<detailed_description>The study prospective , multicenter , single-arm study involve 4 center US . The subject population subject indication percutaneous coronary intervention ( PCI ) stent implantation stable angina and/or silent ischemia . Twelve ( 12 ) consecutive patient refer PCI possible PCI suspect proven coronary artery disease screen consent . Twelve ( 12 ) consecutive patient refer PCI possible PCI suspect proven coronary artery disease screen consent . Patients ACS eligible . Patients consider enrolled eligible receive BioNIR stent successful uncomplicated cross target lesion successful uncomplicated lesion preparation ( pre-dilatation ) need . At least 30 % ( 4 subject ) receive one stent sufficiently long stent total implant stent dose &gt; 1.5 time ridaforolimus dose workhorse BioNIR stent ( 3.0x17 mm ) . For patient , total 14 blood sample collect follow time point : immediately prior first stent implant time 0 , 10 30 minute , 1 , 2 , 4 , 8 , 12 , 24±6 , 48±12 , 72±12 , 168±36 ( 7 day ) , 336±36 ( 14 day ) 720±36 hour ( 30 day ) first BioNIR stent implantation . Whole blood concentration ridaforolimus determine use validated high performance liquid chromatography mass spectrometry/mass spectrometry ( HPLC-MS/MS ) method . If two consecutive measurement available demonstrate ridaforolimus level detection limit assay , level subsequent time point need measure . Relationship BIONICS STUDY : The general angiographic inclusion exclusion criterion identical pivotal BIONICS trial exception Acute Coronary Syndrome ( ACS ) patient exclude . Clinical data collect identical manner BIONICS study . ( Clinical follow-up perform 30 day , 6 month , 1 , 2 , 3 , 4 , 5 year post enrollment . ) The following pharmacokinetic parameter evaluate : maximum concentration ( Cmax ) , Cmax adjust treatment dose , time maximum concentration ( tmax ) , time last quantifiable concentration ( tlast ) , half-life time ( t1/2 ) , total area concentration-time curve time 0 tlast ( AUC0-tlast ) , total area concentration-time curve time 0 tlast ( AUC0-t∞ ) total body clearance ( CL ) . AUCs normalize treatment dose also derive . 12 subject enrol order evaluate pharmacokinetic parameter ridaforolimus release BioNIR stent . The number subject choose base experience literature 'limus ' drug eluting stent well specific request FDA .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>General Inclusion : 1 . Stable patient ( nonACS ) indication possible PCI stable angina , and/or silent ischemia ( absence symptom visually estimate target lesion diameter stenosis ≥70 % , positive noninvasive stress test , Fractional Flow Reserve ( FFR ) ≤0.80 must present ) . 2 . Patient willing able provide inform write consent comply followup visit test schedule Angiographic 1 . Target lesion ( ) must locate native coronary artery bypass graft conduit visually estimate diameter ≥2.5mm ≤4.25mm 2 . Complex lesion allow include calcified lesion ( lesion preparation scoring/cutting rotational atherectomy allow ) , presence thrombus nonocclusive require thrombectomy , chronic total occlusion ( CTO ) , bifurcation lesion ( except plan dual stent implantation ) , ostial RCA lesion , tortuous lesion , bare metal stent restenotic lesion , protect leave main lesion , saphenous vein graft lesion . 3 . Overlapping stent allow General 1 . PCI previous BioNIR stent implantation . 2 . ACS within 1 month enrollment . 3 . Patients receive strong CYP3A inhibitor inducer Ketoconazole Rifampin . 4 . PCI within 24 hour precede baseline procedure . 5 . Nontarget lesion PCI target vessel within 12 month baseline procedure . 6 . History stent thrombosis . 7 . Cardiogenic shock ( defined persistent hypotension ( systolic blood pressure &lt; 90 mm/Hg 30 minute ) require pressor hemodynamic support , include intra aortic balloon pumping ( IABP ) . 8 . Subject intubate . 9 . Known leave ventricular ejection fraction ( LVEF ) &lt; 30 % . 10 . Relative absolute contraindication duale antiplatelet therapy ( DAPT ) 12 month ( include plan surgery delay ) 11 . Subject indication chronic oral anticoagulant treatment ( either vitamin K antagonists novel anticoagulant ( NOACs ) 12 . Calculated creatinine clearance &lt; 30 mL/min use CockcroftGault equation . 13 . Hemoglobin &lt; 10 g/dL . 14 . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 . 15 . White blood cell ( WBC ) count &lt; 3,000 cells/mm3 . 16 . Clinically significant liver disease . 17 . Active peptic ulcer active bleeding site . 18 . Bleeding site within prior 8 week require active medical surgical attention . 19 . If femoral access plan , significant peripheral arterial disease precludes safe insertion 6French ( 6F ) sheath . 20 . History bleed diathesis/coagulopathy/will refuse blood transfusion . 21 . Cerebrovascular accident transient ischemic attack within past 6 month , permanent neurologic defect attribute cerebrovascular accident ( CVA ) . 22 . Known allergy study stent component , e.g . cobalt , nickel , chromium , molybdenum , Carbosil® , PBMA , Biolinx polymer , limus drug ( ridaforolimus , zotarolimus , tacrolimus , sirolimus , everolimus , similar drug analogue derivative similar compound ) . 23 . Known allergy protocolrequired concomitant medication aspirin , DAPT ( clopidogrel , prasugrel , ticagrelor ) , heparin bivalirudin , iodinate contrast adequately premedicated . 24 . Any comorbid condition may cause noncompliance protocol ( e.g . dementia , substance abuse , etc . ) reduce life expectancy &lt; 24 month ( e.g . cancer , severe heart failure , severe lung disease ) . 25 . Patient participate plan participate investigational drug device clinical trial reach primary endpoint . 26 . Women pregnant breastfeeding ( woman childbearing potential must negative pregnancy test within 1week treatment ) . 27 . Women intend become pregnant within 12 month baseline procedure ( woman childbearing potential sexually active must agree use reliable method contraception time screen 12 month baseline procedure ) . 28 . Patient receive / wait list organ transplant . 29 . Patient receive schedule receive chemotherapy within 30 day time baseline procedure . 30 . Patient receive oral intravenous immunosuppressive therapy know lifelimiting immunosuppressive disease ( e.g. , HIV ) . Corticosteroids allow Angiographic exclusion criterion : 31 . Target lesion two ( 2 ) major coronary artery ( ie , two leave anterior descend artery [ LAD ] , LCX , RCA ) include respective branch ( Ramus Intermedius define branch LCX ) . 32 . More two target lesion per target vessel plan ( two lesion separate less 10 mm cover single stent consider one lesion ) . 33 . More 100mm length plan study stenting entire coronary tree . 34 . Occlusive thrombus and/or thrombus require thrombectomy target vessel . 35 . Unprotected leave main lesion ≥30 % , plan unprotected leave main intervention . 36 . Ostial LAD LCX target lesion ( stenting diseased segment within 5 mm unprotected leave main coronary artery ) . 37 . Target Bifurcation lesion plan dual stent implantation . 38 . Stenting target lesion due DES restenosis . 39 . Another lesion target nontarget vessel ( include side branch ) present require high probability require PCI within 12 month baseline procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>coronary luminal diameter</keyword>
	<keyword>lesion</keyword>
	<keyword>vessel</keyword>
</DOC>